Response to acalabrutinib and best change in tumor size. (A) ORR was assessed in all patients who received ≥1 dose of acalabrutinib. (B) Waterfall plot showing the maximum percent change from baseline in the sum of product diameter (SPD) by investigator assessment for all treated patients with tumor assessments (N = 97). Two patients without postbaseline overall response assessment were excluded. SD, stable disease.